BEDFORD, Mass., Sept. 3 Insulet Corporation(Nasdaq: PODD), the leader in patch pump technology with its OmniPod(R)Insulin Management System, today announced the appointment of William "Bill"D. Arthur III as Vice President of Business Development. In this role, Mr.Arthur will lead the company's business development strategy, includingpursuing opportunities to expand the market for the OmniPod System in newapplications and geographies.
"We are delighted to welcome Bill to the Insulet team. Bill is an expertin the infusion pump market and his experience will be a tremendous asset tothe Company as we seek additional applications for the OmniPod System," saidDuane DeSisto, Insulet's president and chief executive officer.
Most recently, Mr. Arthur served as President and COO of SpectRx, Inc.,where he oversaw the design, contract manufacture and world-wide marketing ofthe company's insulin pump infusion set disposables. Previously, Mr. Arthurspent eight years at MiniMed, Inc. as Vice President of Sales andReimbursement, where he helped drive annual sales of insulin infusion pumpsfrom $6 million to over $294 million. Mr. Arthur was also Founder, President,and CEO of MedFusion, Inc., a developer of syringe infusion pumps. Hisexperience also includes roles at PaceSetter Systems, Inc., Auto-Syringe, Inc.and Becton-Dickinson & Company. Mr. Arthur holds a Bachelor of Science degreein Microbiology from Pennsylvania State University.
About Insulet Corporation
Insulet Corporation is an innovative medical device company dedicated toimproving the lives of people with diabetes. The Company's OmniPod InsulinManagement System is a revolutionary, discreet and easy-to-use insulininfusion system that features two easy-to-use parts with no tubing andfully-automated cannula insertion. Through the OmniPod System, Insulet seeksto expand the use of continuous subcutaneous insulin infusion (CSII) therapyamong people with insulin-dependent diabetes. Founded in 2000, Insulet isbased in Bedford, MA.
This press release contains forward-looking statements concerningInsulet's expectations, anticipations, intentions, beliefs or strategiesregarding the future, including those related to its revenues, patient base,manufacturing capacity, expenses, product costs, sales and marketing efforts,financial performance and Insulet's ability to successfully develop, marketand sell the OmniPod for non-diabetes drug delivery applications. Theseforward-looking statements are based on its current expectations and beliefsconcerning future developments and their potential effects on it. There can beno assurance that future developments affecting it will be those that it hasanticipated. These forward-looking statements involve a number of risks,uncertainties (some of which are beyond its control) or other assumptions thatmay cause actual results or performance to be materially different from thoseexpressed or implied by these forward-looking statements. These risks anduncertainties include, but are not limited to: risks associated with Insulet'sdependence on the OmniPod System; Insulet's ability to achieve and maintainmarket acceptance of the OmniPod System; potential manufacturing problems,including damage, destruction or loss of any or Insulet's automated assemblyunits or difficulties in implementing its automated manufacturing strategy;potential problems with sole source or other third-party suppliers on whichInsulet is dependent; Insulet's ability to obtain favorable reimbursement fromthird-party payors for the OmniPod System and potential adverse changes inreimbursement rates or policies relating to the OmniPod; potential adverseeffects resulting from competition with competitors; technological innovationsadversely affecting the Company's business; potential termination of Insulet'slicense to incorporate a blood glucose meter into the O